Clinical Trial: Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904806) titled 'Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis' on Oct. 23.

Brief Summary: This is a phase 2, double-blind, randomized, controlled, multicenter trial evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of 2 VIS954 dosing regimens in patients with moderate to severe acute anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV).

Study Start Date: Dec. 15

Study Type: INTERVENTIONAL

Condition: Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Intervention: DRUG: VIS954

SC injection

DRUG: Standard Of Care (SOC)

Glucocorticoids and rituximab or cy...